New shot targets Hard-to-Treat blood cancers in early trial
NCT ID NCT07493174
First seen Apr 02, 2026 · Last updated May 10, 2026 · Updated 5 times
Summary
This early study tests a new injection called SYS6055 in 86 adults with B-cell blood cancers (like leukemia or lymphoma) that returned or didn't respond to standard treatments. The main goals are to check safety, find the best dose, and see if it shrinks tumors. It's a first step to see if this approach is worth studying further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.